Article
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
European journal of clinical pharmacology - 1 Apr 2018
Novkovic Mirjana, Matic Dragan, Kusic-Tisma Jelena, Antonijevic Nebojsa, Radojkovic Dragica, Rakicevic Ljiljana
Abstract excerpt
PURPOSE: Bleeding is one of the possible adverse events during clopidogrel therapy. The CYP2C19 gene is the most significant genetic factor which influences response to clopidogrel treatment. We aimed to examine the contribution of the CYP2C19 gene to bleeding occurrence during clopidogrel therapy in Serbian patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
